Literature DB >> 33483715

Recent advances and discoveries in the mechanisms and functions of CAR T cells.

Rebecca C Larson1,2, Marcela V Maus3,4.   

Abstract

This Review discusses the major advances and changes made over the past 3 years to our understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the field has gained insight into how various molecular modules of the CAR influence signalling and function. We report on mechanisms of toxicity and resistance as well as novel engineering and pharmaceutical interventions to overcome these challenges. Looking forward, we discuss new targets and indications for CAR T cell therapy expected to reach the clinic in the next 1-2 years. We also consider some new studies that have implications for the future of CAR T cell therapies, including changes to manufacturing, allogeneic products and drug-regulatable CAR T cells.

Entities:  

Year:  2021        PMID: 33483715     DOI: 10.1038/s41568-020-00323-z

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  167 in total

1.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors:  David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

2.  T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Authors:  Michael Kalos; Bruce L Levine; David L Porter; Sharyn Katz; Stephan A Grupp; Adam Bagg; Carl H June
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

Review 3.  The T-body approach: potential for cancer immunotherapy.

Authors:  Z Eshhar; N Bach; C J Fitzer-Attas; G Gross; J Lustgarten; T Waks; D G Schindler
Journal:  Springer Semin Immunopathol       Date:  1996

4.  A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.

Authors:  Michael H Kershaw; Jennifer A Westwood; Linda L Parker; Gang Wang; Zelig Eshhar; Sharon A Mavroukakis; Donald E White; John R Wunderlich; Silvana Canevari; Linda Rogers-Freezer; Clara C Chen; James C Yang; Steven A Rosenberg; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

5.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Authors:  Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

6.  In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.

Authors:  P Hwu; J C Yang; R Cowherd; J Treisman; G E Shafer; Z Eshhar; S A Rosenberg
Journal:  Cancer Res       Date:  1995-08-01       Impact factor: 12.701

7.  Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.

Authors:  I Stancovski; D G Schindler; T Waks; Y Yarden; M Sela; Z Eshhar
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422

8.  Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells.

Authors:  P Vandenberghe; G J Freeman; L M Nadler; M C Fletcher; M Kamoun; L A Turka; J A Ledbetter; C B Thompson; C H June
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307

9.  Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.

Authors:  A Krause; H F Guo; J B Latouche; C Tan; N K Cheung; M Sadelain
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

10.  Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.

Authors:  P Hwu; G E Shafer; J Treisman; D G Schindler; G Gross; R Cowherd; S A Rosenberg; Z Eshhar
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

View more
  96 in total

1.  SILAC Phosphoproteomics Reveals Unique Signaling Circuits in CAR-T Cells and the Inhibition of B Cell-Activating Phosphorylation in Target Cells.

Authors:  Alijah A Griffith; Kenneth P Callahan; Nathan Gordo King; Qian Xiao; Xiaolei Su; Arthur R Salomon
Journal:  J Proteome Res       Date:  2022-01-11       Impact factor: 4.466

Review 2.  Immunogenic cell stress and death.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Claudia Galassi; Laurence Zitvogel
Journal:  Nat Immunol       Date:  2022-02-10       Impact factor: 25.606

Review 3.  Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.

Authors:  Alain E Andrea; Andrada Chiron; Sarah Mallah; Stéphanie Bessoles; Guillaume Sarrabayrouse; Salima Hacein-Bey-Abina
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

4.  Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment.

Authors:  Yun-Ju Ma; Hai-Ping Dai; Qing-Ya Cui; Wei Cui; Wen-Juan Zhu; Chang-Ju Qu; Li-Qing Kang; Ming-Qing Zhu; Xia-Ming Zhu; Dan-Dan Liu; Yu-Feng Feng; Hong-Jie Shen; Tian-Hui Liu; Hui-Ying Qiu; Lei Yu; De-Pei Wu; Xiao-Wen Tang
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

Review 5.  Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.

Authors:  Leila Amini; Sara K Silbert; Nirali N Shah; Mohamed Abou-El-Enein; Shannon L Maude; Loretta J Nastoupil; Carlos A Ramos; Renier J Brentjens; Craig S Sauter
Journal:  Nat Rev Clin Oncol       Date:  2022-03-22       Impact factor: 66.675

6.  Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Adam Goldman; Elad Maor; David Bomze; Jennifer E Liu; Joerg Herrmann; Joshua Fein; Richard M Steingart; Syed S Mahmood; Wendy L Schaffer; Miguel-Angel Perales; Roni Shouval
Journal:  J Am Coll Cardiol       Date:  2021-11-02       Impact factor: 24.094

7.  ROR1-targeting switchable CAR-T cells for cancer therapy.

Authors:  Haiyong Peng; Thomas Nerreter; Katrin Mestermann; Jakob Wachter; Jing Chang; Michael Hudecek; Christoph Rader
Journal:  Oncogene       Date:  2022-07-20       Impact factor: 8.756

Review 8.  Charting roadmaps towards novel and safe synergistic immunotherapy combinations.

Authors:  Miguel F Sanmamed; Pedro Berraondo; Maria E Rodriguez-Ruiz; Ignacio Melero
Journal:  Nat Cancer       Date:  2022-06-28

Review 9.  Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.

Authors:  Kyu Sic You; Yong Weon Yi; Jeonghee Cho; Jeong-Soo Park; Yeon-Sun Seong
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18

Review 10.  Turning enemies into allies-reprogramming tumor-associated macrophages for cancer therapy.

Authors:  Martina Molgora; Marco Colonna
Journal:  Med (N Y)       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.